ViroPharma forges ahead with C Diff preventative
This article was originally published in Scrip
ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.